omapatrilat proposed trade name vanlev experimental antihypertensive agent never inhibits neprilysin neutral endopeptidase nep angiotensinconverting enzyme ace nep inhibition results elevated natriuretic peptide levels promoting natriuresis diuresis vasodilation reductions preload ventricular remodeling discovered developed bristolmyers squibb failed clinical trials potential treatment congestive heart failure due safety concerns causing omapatrilat angioedema attributed dual mechanism action inhibiting angiotensinconverting enzyme ace neprilysin neutral endopeptidase enzymes responsible metabolism bradykinin causes vasodilation angioedema airway obstruction drug article relating cardiovascular system stub help wikipedia expanding ithttpsenwikipediaorgwikiomapatrilat